Use of psychotropic medications in Italian children and adolescents

European Journal of Pediatrics

Volumn 166, Issue 4, 2007, Pages 339-347

  Clavenna, Antonio ^a   Rossi, Elisa ^b   DeRosa, Marisa ^b   Bonati, Maurizio ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CINECA   (Italy)

Author keywords

Adolescent; Child; Drug utilization; Pediatrics; Psychotropic drugs

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENCE; ARTICLE; DATA BASE; DEPRESSION; DRUG UTILIZATION; HUMAN; ITALY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; ITALY; MALE; PSYCHOTROPIC DRUGS;

EID: 33847120202     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-006-0244-7     Document Type: Article

References (52)

1. Abi Khaled L, Ahmad F, Brogan T, Fearnley J, Graham J, MacLeod S, McCormick J (2003) Prescription medicine use by one million Canadian children. Paediatrics Child Health 8(Suppl A):34A-42A
2. Aman MG, De Smedt GD, Derivan A, Lyons B, Findling RL (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psichiatry 159:1337-1346
3. American Academy of Child and Adolescent Psychiatry (1998) Practice parameters for the assessment and the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 37(10S):27S-45S
4. Ansorge MS, Zhou M, Lira A, Hen R, Ginrich JA (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306:879-881
5. Bennett K, Teeling M, Feely J (2005) Overprescribing antidepressants to children: pharmacoepidemiological study in primary care. BMJ 331:1451-1452
6. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C (2006) An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 16:59-75
7. Bonati M, Clavenna A (2005) The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry 17:181-188
8. Brooks SJ, Kutcher S (2003) Diagnosis and measurement of anxiety disorder in adolescents: a review of commonly used instruments. J Child Adolesc Psychopharmacol 13:351-400
9. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, De Battista A, Hoyme HE (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402-408
10. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT (2004) Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372-394
11. Clavenna A, Bonati M (2006) Epidemiological aspects of drug use. In: Jacqz-Aigrain E, Choonara I (eds) Paediatric Clinical Pharmacology. Taylor & Francis, New York, pp 73-83
12. Clavenna A, Bonati M, Rossi E, De Rosa M (2004) Increase in non-evidence based use of antidepressants in children is cause for concern. BMJ 328:711-712
13. Committee on Safety of Medicines (2003) Selective serotonin reuptake inhibitors - use in children and adolescents with major depressive disorder. Available at http://www.info.doh.gov.uk/doh/embroadcast.nsf/0/ 183a970c6d74afad80256df800330c99$FILE/CEM2003-20.doc. Accessed 5 May 2006
14. Coyle JT (2000) Psychotropic drug use in very young children. JAMA 283:1059-1060
15. Delate T, Gelenberg AJ, Simmons VA, Motheral BR (2004) Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatric Services 55:387-391
16. Duff G (2003) Safety of seroxat (paroxetine) in children and adolescents under 18 years - contraindication in the treatment of depressive illness. Available at: http://www.mhra.gov.uk/home/groups/plp/documents/ drugsafetymessage/con019507.pdf. Accessed 5 May 2006
17. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance ALA, Tyl Y, Luk ESL (2003) Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111:372-375
18. EMEA (2005) European Medicines Agency finalises review of antidepressants in children and adolescents. Available at: http://www.emea.eu.int/pdfs/human/ press/12891805en.pdf. Accessed 5 May 2006
19. Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C (2006) Paroxetine treatment in children and adolescents with major depressive disorder. A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 45:6 (in press)
20. Food and Drug Administration (2004) Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. Available at http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm. Accessed 5 May 2006
21. Food and Drug Administration (2003) FDA Talk Paper. FDA approves Prozac for pediatric use to treat depression and OCD. Available at http://www.fda.gov/ bbs/topics/ANSWERS/2003/ANS01187.html. Accessed 5 May 2006
22. Food and Drug Administration (2003) FDA Talk Paper. FDA statement regarding the anti-depressant Paxil for pediatric population. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01203.html. Accessed 5 May 2006)
23. Fegert JM, Kölch M, Magno Zito J, Glaeske G, Janhsen K (2006) Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197-206
24. Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive compulsive disorder. Am J Psychiatry 160:1919-1928
25. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339
26. Hazell P, O'Connell D, Heathcote D, Henry D (2002) Tricyclic drugs for depression in children and adolescents. The Cochrane database of systematic reviews, issue 2, article no.: CD002317. DOI 10.1002/14651858.CD002317. Accessed 5 May 2006
27. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ 328:879-883
28. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagina OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772
29. Kondro W, Sibbald B (2004) Drug company experts advised staff to withhold data about SSRI use in children. Can Med Assoc J 170:783
30. Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D, Wagner KD (2006) ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31:473-492
31. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman M G, Arnold L E, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioural problems. N Engl J Med 347:314-321
32. Medawar C (1997) The antidepressant web - marketing depression and making medicines work. Int J Risk & Safety in Medicine 10:75-126
33. Ministero della Salute (2003) Nuove informazioni sulla sicurezza delle specialità medicinali contenenti paroxetina nel trattamento della malattia depressiva nei bambini e adolescenti al di sotto di 18 anni. Bollettino di Informazione sui Farmaci 5-6:207
34. Moynihan R, Cassels A (2005) Advertising disease. Premenstrual dysphoric disorder. In: Selling sickness. How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books, pp 99-118
35. Murray ML, Thompson M, Santosh PJ, Wong ICK (2005) Efficacy of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Safety 28:1151-1157
36. Murray ML, De Vries CS, Wong ICK (2004) A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child 89:1098-1102
37. National Institute for Health and Clinical Excellence (2005) Clinical guideline 28. Depression in children and young people: identification and management in primary, community and secondary care. National Institute for Health and Clinical Excellence, London
38. Phillips CB (2006) Medicine goes to school: teachers as sickness brokers for ADHD. PLoS Med 3(4):e182
39. Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro M (2004) Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 59:825-831
40. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D (2003) When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160:734-740
41. Raz A (2006) Perspectives on the efficacy of antidepressants for child and adolescent depression. PloS Med 3(1):e9
42. Safer DJ, Magno Zito J (2006) Treatment-emergent adverse events from selective serotinin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 16:159-169
43. Schirm E, Tobi H, de Jong-van den Berg LTW (2003) Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 111:291-295
44. Schirm E, Tobi H, Magno Zito J, de-Jong-van den Berg LTW (2001) Psychotropic medication in children: a study from The Netherlands. Pediatrics 108: e25 Available at: http://www.pediatrics.org/cgi/content/full/108/2/e25. Accessed 5 May 2006
45. Serreau R, Le Heuzey MF, Gilbert A, Mouren MC, Jacqz-Aigrain E (2004) Unlicensed and off-label use of psychotropic medications in French children: A prospective study. Paediatr Perinat Drug Ther 6:14-19
46. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-e641. Available at: http://www.pediatrics.org/cgi/doi/10.1542/peds.2003-0264-F. Accessed 5 May 2006
47. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; The Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psichiatry 41:1026-1036
48. Tischler B, Patriasz K, Beresford J, Bunting R (1972) Experience with pericyazine in profoundly and severe retarded children. Can Med Assoc J 106:103-141
49. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K (2006) A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280-288
50. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE (2004) A randomized, placebo-controlled trial of citalopram for the treatment of major depressi on in children and adolescents. Am J Psychiatry 161:1079-1083
51. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, Dickerman Z (2002) Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156:696-701
52. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341-1345